Baxter International (NYSE:BAX) Releases Q4 2024 Earnings Guidance

Baxter International (NYSE:BAX) issued an update on its fourth quarter 2024 earnings guidance on Friday morning. The company provided EPS guidance of 0.770-0.810 for the period, compared to the consensus EPS estimate of 0.840. The company issued revenue guidance of -. Baxter International also updated its FY 2024 guidance to 2.900-2.940 EPS.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on BAX. Citigroup increased their price target on Baxter International from $38.00 to $40.00 and gave the company a “neutral” rating in a research note on Tuesday, October 1st. Wells Fargo & Company reduced their target price on Baxter International from $44.00 to $40.00 and set an “equal weight” rating on the stock in a report on Wednesday, August 7th. JPMorgan Chase & Co. cut their price target on shares of Baxter International from $44.00 to $42.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 7th. The Goldman Sachs Group lifted their price objective on shares of Baxter International from $36.00 to $40.00 and gave the stock a “neutral” rating in a research note on Thursday, August 8th. Finally, Morgan Stanley downgraded shares of Baxter International from an “equal weight” rating to an “underweight” rating and lowered their target price for the company from $39.00 to $30.00 in a research note on Monday, July 15th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat, Baxter International presently has a consensus rating of “Hold” and a consensus target price of $41.20.

Baxter International Stock Down 3.9 %

NYSE BAX traded down $1.40 during trading on Friday, hitting $34.64. The stock had a trading volume of 6,636,750 shares, compared to its average volume of 2,694,846. Baxter International has a 12 month low of $32.48 and a 12 month high of $44.01. The company has a debt-to-equity ratio of 1.35, a quick ratio of 0.91 and a current ratio of 1.40. The company’s 50-day moving average price is $37.39 and its two-hundred day moving average price is $36.12. The company has a market capitalization of $17.67 billion, a PE ratio of 7.13, a P/E/G ratio of 1.22 and a beta of 0.60.

Baxter International (NYSE:BAX) last announced its quarterly earnings data on Friday, November 8th. The medical instruments supplier reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.78 by $0.02. The business had revenue of $3.85 billion for the quarter, compared to analyst estimates of $3.85 billion. Baxter International had a net margin of 16.51% and a return on equity of 18.06%. The firm’s revenue for the quarter was up 3.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.68 earnings per share. As a group, sell-side analysts forecast that Baxter International will post 2.96 EPS for the current year.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.